Stock AnalizInMed Pharmaceuticals Inc. MTRI
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
InMed Pharmaceuticals Inc. (MTRI) is a healthcare company listed in the US with a market value of about $1.1B.
Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is financial health (3/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -77%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 100% below the current price.
Score: 0.6 / 5
Checks passed
- More cash than debt, or low debt to equity
- Interest covered more than 5 times
- Debt below 3 years of free cash flow
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 7 years
| Fiscal year | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue | — | $5M | $5M | $4M | $1M | $2M | — |
| Net income | -$13M | -$8M | -$8M | -$8M | -$19M | -$10M | -$9M |
| Free cash flow | — | — | -$7M | -$7M | -$16M | -$10M | -$7M |
| EPS (diluted) | $-3.12 | $-8.36 | $-20.14 | $-65.00 | $-663.40 | $-759.20 | $-855.00 |
| Net margin | — | -165.1% | -166.9% | -192.2% | -1361.9% | -535.9% | — |
| ROIC | — | -48.4% | -59.6% | -50.3% | -148.4% | -103.8% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Is InMed Pharmaceuticals stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 100% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does InMed Pharmaceuticals pay a dividend?
Not currently.
Is InMed Pharmaceuticals a good stock to buy?
We do not give buy or sell advice. InMed Pharmaceuticals scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.